ResMed reported higher sales and net income for its second quarter and first half of fiscal 2026. The company declared a quarterly dividend of $0.60 per share. Over the past 90 days, ResMed's share price returned 2.98%, and the one year total shareholder return was 10.96%. The company is conducting a clinical trial to test the APAP Pressure Match tool, a software designed to improve CPAP pressure settings for sleep apnea patients. This tool uses personalized data to fine-tune pressure ranges. The trial is currently in the setup phase and not yet recruiting patients. These developments occurred as post-earnings volatility subsided and the healthcare sector showed strength.
Read full analysisResMed reported higher sales and net income for its second quarter and first half of fiscal 2026. The company declared a quarterly dividend of $0.60 per share. Over the past 90 days, ResMed's share price returned 2.98%, and the one year total shareholder return was 10.96%. The company is conducting a clinical trial to test the APAP Pressure Match tool, a software designed to improve CPAP pressure settings for sleep apnea patients. This tool uses personalized data to fine-tune pressure ranges. The trial is currently in the setup phase and not yet recruiting patients. These developments occurred as post-earnings volatility subsided and the healthcare sector showed strength.
ResMed is a medical device company specializing in sleep apnea treatment, best known for its CPAP machines and related respiratory care products. The company has recently pivoted to frame GLP-1 weight loss drugs as a growth opportunity rather than a threat, arguing that patients on drugs like Ozempic still need sleep apnea screening. Today's move appears driven by broad healthcare sector strength rather than any company-specific development.